Cover Image
市場調查報告書

PharmaPoint:HPV(人類乳突病毒)疫苗 - 全球醫藥品的預測與市場分析

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 305465
出版日期 內容資訊 英文 188 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:HPV(人類乳突病毒)疫苗 - 全球醫藥品的預測與市場分析 PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 188 Pages
簡介

HPV(人類乳突病毒)疫苗,雖受廣泛認可但是,傳統目標層的青年期女子人口的接種率至今仍低。當初,人類乳突病毒(HPV)疫苗以子宮頸癌的預防疫苗開發上市,不過隨著認識人類乳突病毒(HPV)對其他癌症的作用,由於發現有建議男性定期接種疫苗的國家,促進更廣泛對象的接種。

本報告提供全球人類乳突病毒(HPV)疫苗市場相關調查分析、疾病的概要與指南、競爭情形、主要藥物的詳細資訊(產品說明、安全性、有效性)、SWOT分析、銷售額預測、影響分析(趨勢、推動因素、阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 獎勵接種與接種率

  • 獎勵接種概要
  • 美國
    • 獎勵接種與政策
    • 疫苗接種的範圍
    • 臨床體檢
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 加拿大

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介
    • Gardasil
    • Cervarix

第6章 機會及未滿足需求

  • 概要
  • 針對複數人類乳突病毒(HPV)型的預防
  • 疫苗接種率
  • 疫苗的安全性的認識
  • 人類乳突病毒(HPV)疫苗的認識
  • 人類乳突病毒(HPV)疫苗的價格
  • 在特定層中流行的人類乳突病毒(HPV)型的範圍
  • 疫苗接種的遵從率
  • 對人類乳突病毒(HPV)感染的終身免疫不成立
  • 對子宮頸癌症篩檢的目前需求

第7章 開發平台評估

  • 概要
  • 臨床試驗的測繪
  • 臨床開發中的有潛力疫苗
  • 初期開發階段的創新性人類乳突病毒(HPV)疫苗

第8章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Merck
    • GSK

第9章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲
  • 加拿大

第10章 附錄

圖表

目錄
Product Code: GDHC84PIDR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Highlights

Key Questions Answered

  • What environmental factors limit the uptake of current HPV vaccines?
  • What opportunities exist to overcome these environmental factors?
  • What are the main unmet needs of current HPV vaccines?
  • What technologies are positioned to address these unmet needs?
  • What opportunities will remain for the development of new HPV vaccines?
  • What environmental factors will influence the introduction of novel HPV vaccines?

Key Findings

  • New nine-valent HPV vaccines are expected to be widely adopted following market approval, stealing market share from existing vaccines. Though a high price represents a potential barrier to market access.
  • Significant environmental barriers to HPV vaccination exist, which currently serve to limit vaccine uptake.
  • The emphasis of HPV vaccination is shifting away from an initial focus on cervical cancer prevention in females, towards prevention of a range of cancers in both males and females.
  • The inclusion of males in routine HPV vaccine recommendations will expand the size of the HPV vaccines market

Scope

  • Overview of the latest advances in prophylactic vaccination.
  • Analysis of the future potential for novel and existing HPV vaccines.
  • Key topics covered include unmet needs, opportunities, and drivers and barriers specific to prophylactic HPV vaccines.

Reasons to buy

  • Understand the dynamics of the prophylactic HPV vaccines market, and the unique barriers to market access.
  • Identify opportunities for the development and delivery of HPV vaccines, and to identify emerging players with potentially strong product portfolios.
  • Develop business strategies by understanding the trends shaping and driving the future of prophylactic HPV vaccination.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Gain insight on the challenges associated with delivering prophylactic HPV vaccines and the impact of novel vaccines.
  • Track vaccine sales in the global HPV vaccines market from 2012-2022

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Vaccination Recommendations Overview
  • 4.2. US
    • 4.2.1. Vaccination Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice
  • 4.3. France
    • 4.3.1. Vaccination Recommendations and Policies
    • 4.3.2. Vaccination Coverage
    • 4.3.3. Clinical Practice
  • 4.4. Germany
    • 4.4.1. Vaccination Recommendations and Policies
    • 4.4.2. Vaccination Coverage
    • 4.4.3. Clinical Practice
  • 4.5. Italy
    • 4.5.1. Vaccination Recommendations and Policies
    • 4.5.2. Vaccination Coverage
    • 4.5.3. Clinical Practice
  • 4.6. Spain
    • 4.6.1. Vaccination Recommendations and Policies
    • 4.6.2. Vaccination Coverage
    • 4.6.3. Clinical Practice
  • 4.7. UK
    • 4.7.1. Vaccination Recommendations and Policies
    • 4.7.2. Vaccination Coverage
    • 4.7.3. Clinical Practice
  • 4.8. Japan
    • 4.8.1. Vaccination Recommendations and Policies
    • 4.8.2. Vaccination Coverage
    • 4.8.3. Clinical Practice
  • 4.9. Australia
    • 4.9.1. Vaccination Recommendations and Policies
    • 4.9.2. Vaccination Coverage
    • 4.9.3. Clinical Practice
  • 4.10. Canada
    • 4.10.1. Vaccination Recommendations and Policies
    • 4.10.2. Vaccination Coverage
    • 4.10.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles
    • 5.3.1. Gardasil
    • 5.3.2. Cervarix

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Protection against Multiple HPV Types
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Vaccine Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Perception of Vaccine Safety
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Awareness of HPV Vaccination
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Affordability of HPV Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Coverage of HPV Types Prevalent in Certain Populations
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Vaccine Compliance Rates
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Lifelong Protection from HPV Infection Not Established
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Ongoing Need for Cervical Cancer Screening
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trials by Country
    • 7.2.2. Clinical Trials by Phase and Trial Status
  • 7.3. Promising Vaccines in Clinical Development
    • 7.3.1. V503
    • 7.3.2. Xiamen Innovax (Bivalent Vaccine)
  • 7.4. Innovative HPV Vaccines in Early Development
    • 7.4.1. Low-Cost HPV Vaccines
    • 7.4.2. Universal HPV Vaccines

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Merck
    • 8.3.2. GSK

9. Market Outlook

  • 9.1. Global Markets
    • 9.1.1. Forecast
    • 9.1.2. Drivers and Barriers - Global Issues
  • 9.2. US
    • 9.2.1. Forecast
    • 9.2.2. Key Events
    • 9.2.3. Drivers and Barriers
  • 9.3. France
    • 9.3.1. Forecast
    • 9.3.2. Key Events
    • 9.3.3. Drivers and Barriers
  • 9.4. Germany
    • 9.4.1. Forecast
    • 9.4.2. Key Events
    • 9.4.3. Drivers and Barriers
  • 9.5. Italy
    • 9.5.1. Forecast
    • 9.5.2. Key Events
    • 9.5.3. Drivers and Barriers
  • 9.6. Spain
    • 9.6.1. Forecast
    • 9.6.2. Key Events
    • 9.6.3. Drivers and Barriers
  • 9.7. UK
    • 9.7.1. Forecast
    • 9.7.2. Key Events
    • 9.7.3. Drivers and Barriers
  • 9.8. Japan
    • 9.8.1. Forecast
    • 9.8.2. Key Events
    • 9.8.3. Drivers and Barriers
  • 9.9. Australia
    • 9.9.1. Forecast
    • 9.9.2. Key Events
    • 9.9.3. Drivers and Barriers
  • 9.10. Canada
    • 9.10.1. Forecast
    • 9.10.2. Key Events
    • 9.10.3. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Vaccine Coverage
    • 10.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 10.4.3. Vaccines Included
    • 10.4.4. Vaccine Launch Dates and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Author(s)
    • 10.6.1. Author(s)
    • 10.6.2. Therapy Area Director
    • 10.6.3. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: HPV Vaccine Recommendation Agencies by Country
  • Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
  • Table 5: Routine HPV Vaccine Programs by Region, Italy
  • Table 6: Routine HPV Vaccine Programs by Region, Spain
  • Table 7: Routine HPV Vaccine Programs by Province, Canada
  • Table 8: Marketed Vaccines for HPV, 2014
  • Table 9: Product Profile - Gardasil
  • Table 10: Phase III Efficacy Trials - Gardasil
  • Table 11: Safety Profile - Gardasil
  • Table 12: Gardasil SWOT Analysis, 2014
  • Table 13: Global Sales Forecasts ($m) for Gardasil, 2012-2022
  • Table 14: Product Profile - Cervarix
  • Table 15: Phase III Efficacy Trials - Cervarix
  • Table 16: Safety Profile - Cervarix
  • Table 17: Cervarix SWOT Analysis, 2014
  • Table 18: Global Sales Forecasts ($m) for Cervarix, 2012-2022
  • Table 19: Overall Unmet Needs - Current and Future Level of Attainment
  • Table 20: HPV Vaccines - Clinical Trials by Phase and Status, 2014
  • Table 21: HPV Vaccines - Phase Pipeline, 2014
  • Table 22: Product Profile - V503
  • Table 23: V503 SWOT Analysis, 2013
  • Table 24: Global Sales Forecasts ($m) for V503, 2012-2022
  • Table 25: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
  • Table 26: Key Companies in the HPV Vaccine Market, 2014
  • Table 27: Merck's HPV Vaccine Portfolio Assessment, 2014
  • Table 28: Merck SWOT Analysis, 2014
  • Table 29: GSK's HPV Vaccine Portfolio Assessment, 2014
  • Table 30: GSK SWOT Analysis, 2014
  • Table 31: Global Sales Forecasts ($m) for HPV Vaccines, 2012-2022
  • Table 32: Global HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 33: Sales Forecasts ($m) for HPV Vaccines in the United States, 2012-2022
  • Table 34: Key Events Impacting Sales for HPV Vaccines in the United States, 2012-2022
  • Table 35: United States HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 36: Sales Forecasts ($m) for HPV Vaccines in France, 2012-2022
  • Table 37: Key Events Impacting Sales for HPV Vaccines in France, 2012-2022
  • Table 38: France HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 39: Sales Forecasts ($m) for HPV Vaccines in Germany, 2012-2022
  • Table 40: Key Events Impacting Sales for HPV Vaccines in Germany, 2014
  • Table 41: Germany HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 42: Sales Forecasts ($m) for HPV Vaccines in Italy, 2012-2022
  • Table 43: Key Events Impacting Sales for HPV Vaccines in Italy, 2014
  • Table 44: Italy HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 45: Sales Forecasts ($m) for HPV Vaccines in Spain, 2012-2022
  • Table 46: Key Events Impacting Sales for HPV Vaccines in Spain, 2012-2022
  • Table 47: Spain HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 48: Sales Forecasts ($) for HPV Vaccines in the United Kingdom, 2012-2022
  • Table 49: Key Events Impacting Sales for HPV Vaccines in the United Kingdom, 2012-2022
  • Table 50: United Kingdom HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 51: Sales Forecasts ($) for HPV Vaccines in Japan, 2012-2022
  • Table 52: Key Events Impacting Sales for HPV Vaccines in Japan, 2012-2022
  • Table 53: Japan HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 54: Sales Forecasts ($) for HPV Vaccines in Australia, 2012-2022
  • Table 55: Key Events Impacting Sales for HPV Vaccines in Australia, 2012-2022
  • Table 56: Australia HPV Vaccine Market - Drivers and Barriers, 2013
  • Table 57: Sales Forecasts ($) for HPV Vaccines in Canada, 2012-2022
  • Table 58: Key Events Impacting Sales for HPV Vaccines in Canada, 2012-2022
  • Table 59: Canada HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 60: Key Launch Dates
  • Table 61: Key Patent Expiries
  • Table 62: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Historical and Projected HPV Vaccination Coverage (%) in the United States among 12-Year-Old Females, 2007-2022
  • Figure 2: Historical and Projected HPV Vaccination Coverage (%) in France among 14-Year-Old Females, 2007-2022
  • Figure 3: Historical and Projected HPV Vaccination Coverage (%) in Germany among 17-Year-Old Females, 2009-2022
  • Figure 4: Historical and Projected HPV Vaccination Coverage (%) in Italy among 12-Year-Old Females, 2009-2022
  • Figure 5: Historical and Projected HPV Vaccination Coverage (%) in Spain among 14-Year-Old Females, 2008-2022
  • Figure 6: Historical and Projected HPV Vaccination Coverage (%) in the United Kingdom among 12-Year-Old Females, 2008-2022
  • Figure 7: Historical and Projected HPV Vaccination Coverage (%) in Japan among 16-Year-Old Females, 2012-2022
  • Figure 8: Historical and Projected HPV Vaccination Coverage (%) in Australia among 13-Year-Old Females, 2007-2022
  • Figure 9: Historical and Projected HPV Vaccination Coverage (%) in Canada among 12-Year-Old Females, 2007-2022
  • Figure 10: HPV Vaccines - Clinical Trials by Country, 2014
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
  • Figure 12: Company Portfolio Gap Analysis in HPV Vaccines, 2012-2022
  • Figure 13: Global Sales for HPV Vaccines by Region, 2012-2022
  • Figure 14: Sales for HPV Vaccines in the US by Vaccine Class, 2012-2022
  • Figure 15: Sales for HPV Vaccines in France by Vaccine Class, 2012-2022
  • Figure 16: Sales for HPV Vaccines in Germany by Vaccine Class, 2012-2022
  • Figure 17: Sales for HPV Vaccines in Italy by Vaccine Class, 2012-2022
  • Figure 18: Sales for HPV Vaccines in Spain by Vaccine Class, 2012-2022
  • Figure 19: Sales for HPV Vaccines in the United Kingdom by Vaccine Class, 2012-2022
  • Figure 20: Sales for HPV Vaccines in Japan by Vaccine Class, 2012-2022
  • Figure 21: Sales for HPV Vaccines in Australia by Vaccine Class, 2012-2022
  • Figure 22: Sales for HPV Vaccines in Canada by Vaccine Class, 2012-2022
Back to Top